1
|
Zhang WJ, Chen RQ, Tang X, Li PB, Wang J, Wu HK, Xu N, Zou MF, Luo SR, Ouyang ZQ, Chen ZK, Liao XX, Wu H. Naoxintong capsule for treating cardiovascular and cerebrovascular diseases: from bench to bedside. Front Pharmacol 2024; 15:1402763. [PMID: 38994201 PMCID: PMC11236728 DOI: 10.3389/fphar.2024.1402763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2024] [Accepted: 06/06/2024] [Indexed: 07/13/2024] Open
Abstract
Naoxintong Capsule (NXT), a renowned traditional Chinese medicine (TCM) formulation, has been broadly applied in China for more than 30 years. Over decades, accumulating evidences have proven satisfactory efficacy and safety of NXT in treating cardiovascular and cerebrovascular diseases (CCVD). Studies have been conducted unceasingly, while this growing latest knowledge of NXT has not yet been interpreted properly and summarized comprehensively. Hence, we systematically review the advancements in NXT research, from its chemical constituents, quality control, pharmacokinetics, to its profound pharmacological activities as well as its clinical applications in CCVD. Moreover, we further propose specific challenges for its future perspectives: 1) to precisely clarify bioactivities of single compound in complicated mixtures; 2) to evaluate the pharmacokinetic behaviors of NXT feature components in clinical studies, especially drug-drug interactions in CCVD patients; 3) to explore and validate its multi-target mechanisms by integrating multi-omics technologies; 4) to re-evaluate the safety and efficacy of NXT by carrying out large-scale, multicenter randomized controlled trials. In brief, this review aims to straighten out a paradigm for TCM modernization, which help to contribute NXT as a piece of Chinese Wisdom into the advanced intervention strategy for CCVD therapy.
Collapse
Affiliation(s)
- Wei-jian Zhang
- Department of Neurosurgery, First People’s Hospital of Foshan, Foshan, Guangdong, China
| | - Rui-qi Chen
- Guangdong Engineering and Technology Research Center for Quality and Efficacy Reevaluation of Post-market Traditional Chinese Medicine, Guangdong Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, Guangzhou, China
| | - Xuan Tang
- Guangdong Engineering and Technology Research Center for Quality and Efficacy Reevaluation of Post-market Traditional Chinese Medicine, Guangdong Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, Guangzhou, China
| | - Pei-bo Li
- Guangdong Engineering and Technology Research Center for Quality and Efficacy Reevaluation of Post-market Traditional Chinese Medicine, Guangdong Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, Guangzhou, China
| | - Jian Wang
- Department of Neurosurgery, Foshan Sanshui District People’s Hospital, Foshan, Guangdong, China
| | - Hai-ke Wu
- Department of Neurology, Foshan Hospital of Traditional Chinese Medicine, Foshan, Guangdong, China
| | - Ning Xu
- Second People’s Hospital of Foshan, Foshan, Guangdong, China
| | - Ming-fei Zou
- Second People’s Hospital of Foshan, Foshan, Guangdong, China
| | - Sen-rong Luo
- Guangdong Medical University, Zhanjiang, Guangdong, China
| | - Zi-qi Ouyang
- Guangdong Medical University, Zhanjiang, Guangdong, China
| | - Zhi-kai Chen
- Guangdong Medical University, Zhanjiang, Guangdong, China
| | - Xu-xing Liao
- Department of Neurosurgery, First People’s Hospital of Foshan, Foshan, Guangdong, China
| | - Hao Wu
- Guangdong Engineering and Technology Research Center for Quality and Efficacy Reevaluation of Post-market Traditional Chinese Medicine, Guangdong Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, Guangzhou, China
| |
Collapse
|
2
|
Wang G, Qiao Y, Zhao Y, Song Y, Li M, Jin M, Yang D, Yin J, Li J, Liu W. Beauvericin exerts an anti-tumor effect on hepatocellular carcinoma by inducing PI3K/AKT-mediated apoptosis. Arch Biochem Biophys 2023; 745:109720. [PMID: 37611353 DOI: 10.1016/j.abb.2023.109720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2023] [Revised: 08/15/2023] [Accepted: 08/19/2023] [Indexed: 08/25/2023]
Abstract
Beauvericin is a world-spread mycotoxin isolated from the traditional Chinese medicine, Bombyx batryticatus (BB), which has been widely used to treat various neoplastic diseases. This study investigated the anti-hepatocellular carcinoma (HCC) activity of beauvericin and its potential mechanism. In this study, H22-bearing mice were intraperitoneally injected with 3, 5, 7 mg/kg of beauvericin once per-week over a three-week period. TUNEL staining determined the extent of tumor apoptosis induced by beauvericin. ELISA kits detected the level of IL-2, Perforin, and TNF-α, IFN-γ level in the serum. H22 hepatoma cells were exposed to beauvericin (5, 10, and 20 μmol/L) to investigate the underlying pathway. CCK-8 assay was used to observe the influence of beauvericin on the growth of H22 cells. Flow cytometry was used to detect the cell apoptosis and ROS level. Western blotting was performed to detect apoptotic and PI3K/AKT pathway protein production. The results showed that beauvericin could remarkably inhibit the growth of HCC in mice, combined with elevated TNF-α and IL-2. In vitro, beauvericin significantly promoted the generation of ROS, up-regulated Bax/Bcl-2 ratio and cleaved caspase-9, cleaved caspase-3 levels, down-regulated p-PI3K/PI3K ratio, p-AKT/AKT ratio, promoted the apoptosis of H22 cells, and inhibited the growth of H22 cells. Remarkably, treatment with PI3K/AKT activator (740Y-P and SC79) could prevent beauvericin-induced H22 cell apoptosis. These findings collectively indicate that beauvericin inhibits HCC growth by inducing apoptosis via the PI3K/AKT pathway.
Collapse
Affiliation(s)
- Gui Wang
- Tianjin Institute of Environmental and Operational Medicine, Tianjin, 300050, China.
| | - Yamei Qiao
- Tianjin Institute of Environmental and Operational Medicine, Tianjin, 300050, China.
| | - Yunyan Zhao
- Tianjin Institute of Environmental and Operational Medicine, Tianjin, 300050, China.
| | - Yuanyuan Song
- Tianjin Institute of Environmental and Operational Medicine, Tianjin, 300050, China.
| | - Mengyang Li
- Tianjin Institute of Environmental and Operational Medicine, Tianjin, 300050, China.
| | - Min Jin
- Tianjin Institute of Environmental and Operational Medicine, Tianjin, 300050, China.
| | - Dong Yang
- Tianjin Institute of Environmental and Operational Medicine, Tianjin, 300050, China.
| | - Jing Yin
- Tianjin Institute of Environmental and Operational Medicine, Tianjin, 300050, China.
| | - Junwen Li
- Tianjin Institute of Environmental and Operational Medicine, Tianjin, 300050, China.
| | - Weili Liu
- Tianjin Institute of Environmental and Operational Medicine, Tianjin, 300050, China.
| |
Collapse
|
3
|
Fan F, Hao L, Zhang S, Zhang Y, Bian Z, Zhang X, Wang Q, Han F. Efficacy of the Jingxin Zhidong Formula for Tic Disorders: A Randomized, Double Blind, Double Dummy, Parallel Controlled Trial. Neuropsychiatr Dis Treat 2022; 18:57-66. [PMID: 35046656 PMCID: PMC8761538 DOI: 10.2147/ndt.s347432] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Accepted: 12/26/2021] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND The Jingxin Zhidong formula (JXZDF), a traditional Chinese medicine, has been widely used to treat tic disorder (TD) in China. However, its efficacy has not yet been evaluated in a randomized controlled trial. We aimed to compare the effectiveness and safety of JXZDF and aripiprazole in patients with TD. METHODS In this randomized, double-blind, double-dummy, parallel controlled trial, 120 patients with TD, aged 6-16 years were randomly assigned to receive either JXZDF (n = 60, 17.6 g/day) or aripiprazole (n = 60, 10 mg/day) for 12 weeks. The primary outcome was measured using the Yale Global Tic Severity Scale (YGTSS). Adverse events were assessed using the Treatment Emergent Symptom Scale. RESULTS JXZDF produced greater improvements than aripiprazole in the following YGTSS subscale scores at the endpoint: total tic scores (P = 0.004, 95% CI: 1.085-3.494) and total motor scores (P = 0.004, 95% CI: 0.313-1.739). The difference in rate between the groups was no significant (χ2 = 0.702, degrees of freedom = 1, P = 0.402). The overall incidence of adverse events was significantly lower in the JXZDF group than in the aripiprazole group (0% vs 6.67%, P < 0.001). CONCLUSION JXZDF had a better safety profile than aripiprazole, and it was not inferior in terms of clinical efficacy. JXZDF warrants consideration as a potential treatment option for TD. TRIAL REGISTRATION CHiCTR, ChiCTR2000039601 (Registered November 2, 2020).
Collapse
Affiliation(s)
- Fei Fan
- Department of Paediatrics, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China
| | - Long Hao
- Department of Paediatrics, Beijing Fangshan District Liangxiang Hospital, Beijing, People's Republic of China
| | - Si Zhang
- Department of Paediatrics, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China
| | - Ying Zhang
- Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, People's Republic of China
| | - Zhaoxiang Bian
- Chinese EQUATOR Centre, Hong Kong Chinese Medicine Clinical Study Centre, Chinese Clinical Trial Registry (Hong Kong), School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong, People's Republic of China
| | - Xuan Zhang
- Chinese EQUATOR Centre, Hong Kong Chinese Medicine Clinical Study Centre, Chinese Clinical Trial Registry (Hong Kong), School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong, People's Republic of China
| | - Qiong Wang
- Clinical Medical School, Beijing University of Chinese Medicine, Beijing, People's Republic of China
| | - Fei Han
- Department of Paediatrics, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China
| |
Collapse
|
4
|
Yan H, Kong D, Li X, Luo J, Fan Z, Yang M. Multi-channel electroanalysis of As (III), Hg and Cu in the complex matrix of Bombyx batryticatus after pre-purification. Microchem J 2020. [DOI: 10.1016/j.microc.2020.104707] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|